Summary
Following administration of equivalent oral doses (30mg) of either Prednisone or prednisolone to 5 patients with chronic active liver disease who had failed to respond to therapy, 5 patients with chronic active liver disease in remission induced by Prednisone, and 7 healthy volunteers, corticosteroid concentrations were measured in both serum and urine by radioimmunoassay. Prednisone and prednisolone concentrations in the urine were very similar in all groups, regardless of the drug given. After either treatment, the peak serum concentration and area under the prednisolone serum concentration-time curve were 4 to 5 times those of prednisone. Slight differences among the 3 groups studied were seen in Prednisone and prednisolone pharmacokinetics, but none was significant. It is concluded that the use of Prednisone instead of prednisolone to treat chronic active liver disease can not be implicated as a cause of treatment failure. Indeed, this study suggests that either medication is effective, and this is supported by serum concentrations which suggest a rapid interconversion equilibrium between the 2 corticosteroids.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Colburn, W.A.; Sibley, C.R. and Buller, R.M.: Comparative serum Prednisone and prednisolone concentrations following Prednisone or prednisolone administration to beagle dogs. Journal of Pharmaceutical Sciences 65: 997–1002 (1976).
Davis, M.; Williams, R.; Charkrabarty, J.; English, J.; Marks, V. and Tempere, S.: Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability. British Journal of Clinical Pharmacology 5: 501–505 (1978).
Madsbad, J.; Bjerregaard, B.; Henriksen, J.H.; Juhl, E. and Kehlet, H.: Impaired conversion of Prednisone to prednisolone in patients with liver cirrhosis. Gut 21: 52–56 (1980).
Powell L.W. and Axelsen, E.: Corticosteroids in liver disease: Studies on the biological conversion of Prednisone and plasma protein binding. Gut 13: 690–698 (1972).
Robles, G.; Gil, S. and Uribe M.: Lymphocyte corticosteroid receptors (LCR) determining response to Prednisone therapy in chronic active hepatitis (CAH). Gastroenterology 75: 983 (1978).
Schalm, S.W.; Ammon, H.V. and Summerskill, W.H.J. Failure of customary treatment in chronic active liver disease: Causes and management. Annals of Clinical Research 8: 221–227, (1976).
Schalm, S.W. and Summerskill, W.H.J.: Development of radioimmunoassays for Prednisone and prednisolone: Application to studies of hepatic metabolism of Prednisone. Mayo Clinic Proceedings 51: 761–766 (1976).
Schalm, S.W., Summerskill, W.H.J. and Go, V.L.W.: Prednisone for chronic active liver disease: Pharmacokinetics, including conversion to Prednisone. Gastroenterology 72: 910–932 (1977).
Shull, H.J.; Wilkinson, G.R. and Johnson R.: Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Annals of Internal Medicine 84: 420–426 (1976).
Sierra, J., Podolsky, I. and Uribe M.: La administration de cimetidina reduce las concentraciones séricas de prednisolona en pacientes con hepatitis crónica activa y sujetos normales. Revista de Gastroenterologia de México 45: 308 (1980).
Soloway, R.D.; Summerskill, W.H.J. and Baggenstoss, A.H.: Clinical biochemical and histologic remission of severe chronic active liver disease: A controlled study of treatment and early prognosis. Gastroenterology 63: 820–833 (1972).
Uribe, M. and Go, V.L.W.: Corticosteroid pharmacokinetics in liver disease. Clinical Pharmacokinetics 4: 233–240 (1979).
Uribe, M.; Go, V.L.W. and Summerskitl, W.H.J.. Kinetics and interconversion of Prednisone and prednisolone compared in chronic active liver disease (CALD) [Abstract]. Gastroenterology 71: 932 (1976a).
Uribe, M.; Rojas, S. and Casian, C.: Decreased bioavailability of Prednisone due to antacids in patients with chronic active liver disease and healthy volunteers. Gastroenterology 80: 261–865 (1981).
Uribe, M.; Schalm, S.W.; Summerskill, W.H.J. and Go, V.L.W.: Effect of liquid diet on serum protein binding and prednisolone concentrations after oral Prednisone. Gastroenterology 71: 362–364 (1976b).
Uribe, M.; Schalm, S.W.; Summerskill, W.H.J. and Go, V.L.W.: Oral Prednisone for chronic active liver disease: Dose response and bioavailability studies. Gut 19: 1131–1135 (1978).
Vermulen, A.: The metabolism of 4-14C Prednisone. Journal of Endocrinology 18: 278–291 (1959).
Author information
Authors and Affiliations
Additional information
Dieceased
Rights and permissions
About this article
Cite this article
Uribe, M., Summerskill, W.H.J. & Go, V.L.W. Comparative Serum Prednisone and Prednisolone Concentrations Following Administration to Patients with Chronic Active Liver Disease. Clin Pharmacokinet 7, 452–459 (1982). https://doi.org/10.2165/00003088-198207050-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198207050-00005